Why the study?
Factor Xa antagonists are increasingly used in non-valvular AF, but patient characteristics, prolonged treatment, comorbidities, and drug interactions increase the risk of anticoagulation side effects.
Do factor Xa antagonists improve efficacy and safety compared to vitamin K antagonists in patients with non-valvular atrial fibrillation?
Do factor Xa antagonists improve efficacy and safety compared to vitamin K antagonists in patients with non-valvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This review confirms that factor Xa inhibitors are an effective, safe, and cost-effective alternative to warfarin for stroke prevention in non-valvular atrial fibrillation.
Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events and for prevention of stroke and systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics of patient, a need in prolonged or life-long treatment, concomitant diseases, the use of other drugs interacting with anticoagulants increase the risk of side effects of anticoagulation. We analyzed the current data on the efficacy and safety of Xa factor antagonists, as well as the features of their use in the event of adverse reactions, particularly bleedings. The possibilities of monitoring the efficacy and safety of treatment with these drugs were evaluated.
No takes yet. Share an insight, caveat, or question.
Drozdovа et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: